Trial of a device to keep rheumatoid arthritis in remission
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests a medical device to help people with rheumatoid arthritis stay in remission while on biologic therapy. The goal is to see if the device can prevent flares and maintain disease control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have rheumatoid arthritis as diagnosed by standard criteria.
- Your rheumatoid arthritis has been in remission for at least 6 months.
- You are currently taking a biologic anti-TNF drug (such as infliximab, adalimumab, etanercept, golimumab, or certolizumab).
- You are not already in the process of reducing or extending your biologic doses.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called telitacicept for people with rheumatoid arthritis (RA) that hasn't improved after trying multiple treatments. It aims to see if the drug can reduce joint pain and swelling when other medications have failed.
This study tests a new, AI-powered treatment approach for rheumatoid arthritis. It's for people with active disease who haven't used certain biologic or targeted therapies in the last 6 months.
This study tests a smartphone-based app that tracks hand symptoms to help detect rheumatoid arthritis flares and how well treatment is working. It aims to give patients and doctors an easier way to manage the disease between visits.
This study tests an investigational drug called TLL-018 for people with moderate to severe rheumatoid arthritis who have not improved enough with standard disease-modifying drugs. It aims to see if the drug can reduce joint pain and swelling.
This trial tests an investigational drug for people with moderate-to-severe rheumatoid arthritis who haven't responded well to previous treatments. It aims to see if the drug can reduce joint pain and swelling.
This trial aims to find out if a simple blood test (biomarker) can show whether a lower dose of rituximab will work for people with rheumatoid arthritis. If successful, it could help patients maintain good results with less medicine and fewer side effects.
Hear when a new Rheumatoid Arthritis (RA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.